- Home
- NYT vs MRNA Comparison
NYT vs MRNA Comparison
Compare NYT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- MRNA
- Stock Information
- Founded
- NYT 1851
- MRNA 2010
- Country
- NYT United States
- MRNA United States
- Employees
- NYT N/A
- MRNA N/A
- Industry
- NYT Newspapers/Magazines
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NYT Consumer Discretionary
- MRNA Health Care
- Exchange
- NYT Nasdaq
- MRNA Nasdaq
- Market Cap
- NYT 9.3B
- MRNA 9.8B
- IPO Year
- NYT N/A
- MRNA 2018
- Fundamental
- Price
- NYT $55.27
- MRNA $27.89
- Analyst Decision
- NYT Buy
- MRNA Hold
- Analyst Count
- NYT 6
- MRNA 17
- Target Price
- NYT $60.33
- MRNA $42.40
- AVG Volume (30 Days)
- NYT 1.5M
- MRNA 12.3M
- Earning Date
- NYT 11-03-2025
- MRNA 11-06-2025
- Dividend Yield
- NYT 1.30%
- MRNA N/A
- EPS Growth
- NYT 19.25
- MRNA N/A
- EPS
- NYT 1.93
- MRNA N/A
- Revenue
- NYT $2,661,490,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- NYT $10.20
- MRNA N/A
- Revenue Next Year
- NYT $6.24
- MRNA $9.75
- P/E Ratio
- NYT $28.62
- MRNA N/A
- Revenue Growth
- NYT 7.88
- MRNA N/A
- 52 Week Low
- NYT $44.83
- MRNA $23.15
- 52 Week High
- NYT $62.24
- MRNA $59.73
- Technical
- Relative Strength Index (RSI)
- NYT 31.93
- MRNA 58.77
- Support Level
- NYT $54.51
- MRNA $26.91
- Resistance Level
- NYT $55.93
- MRNA $28.99
- Average True Range (ATR)
- NYT 0.91
- MRNA 1.22
- MACD
- NYT -0.35
- MRNA 0.35
- Stochastic Oscillator
- NYT 14.46
- MRNA 76.78
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.